The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19
Introduction: Infection with SARS-CoV-2 induces a prothrombotic state in patients, by the combination of hyperinflammatory response and hypoxia. In Cuba, the drug called Jusvinza, based on an immunomodulatory peptide, is used for the treatment of patients with COVID-19, who present signs and symptom...
Guardado en:
Autores principales: | Rafael Venegas Rodríguez, Anabel Serrano Díaz, Rubén Peña Ruiz, Raúl Santana Sánchez, Aliusha Rittoles Navarro, Inti Grecesqui Cruz, Liam Manuel Pérez Aguilera, Anadys Segura Fernández, Mabel Hernández-Cedeño, Leticia Rosario Cruz, Deyli Chacón Montano, Gillian Martínez-Donato, Gerardo Guillén-Nieto, María del Carmen Domínguez Horta |
---|---|
Formato: | article |
Lenguaje: | ES |
Publicado: |
ECIMED
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f6eb7ab4857a40099c1ae154c0595594 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19
por: Rafael Venegas Rodríguez, et al.
Publicado: (2021) -
Iron Acquisition and Siderophore Release by Carbapenem-Resistant Sequence Type 258 <named-content content-type="genus-species">Klebsiella pneumoniae</named-content>
por: Victoria I. Holden, et al.
Publicado: (2018) -
A New Take on an Old Remedy: Generating Antibodies against Multidrug-Resistant Gram-Negative Bacteria in a Postantibiotic World
por: Michael P. Motley, et al.
Publicado: (2017) -
TRAP1 in Oxidative Stress and Neurodegeneration
por: Inês Ramos Rego, et al.
Publicado: (2021) -
Production and immune response of recombinant Hsp60 and Hsp70 from the salmon pathogen Piscirickettsia salmonis
por: WILHELM,VIVIAN, et al.
Publicado: (2005)